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Abstract
Purpose Barasertib (AZD1152) is a pro-drug that rapidly
undergoes phosphatase-mediated cleavage in serum to
release barasertib-hQPA, a selective Aurora B kinase
inhibitor that has shown preliminary activity in clinical
studies of patients with acute myeloid leukemia (AML).
The pharmacokinetic (PK), metabolic and excretion pro-
files of barasertib and barasertib-hQPA were characterized
in this open-label Phase I study.
Methods Five patients with poor prognosis AML (newly
diagnosed, relapsed or refractory) received barasertib
1,200 mg as a 7-day continuous infusion every 28 days. On
Day 2 of Cycle 1 only, patients also received a 2-hour
infusion of [14C]-barasertib. Blood, urine and feces sam-
ples were collected at various time points during Cycle 1.
Safety and preliminary efficacy were also assessed.
Results Barasertib-hQPA was extensively distributed to
tissues, with a slow rate of total clearance (CL = 31.4 L/h).
Overall, 72–82 % of radioactivity was recovered, with
approximately double the amount recovered in feces
(mean = 51 %) compared with urine (mean = 27 %). The
main metabolism pathways for barasertib were (1) cleav-
age of the phosphate group to form barasertib-hQPA, fol-
lowed by oxidation and (2) loss of the fluoroaniline moiety
to form barasertib-hQPA desfluoroaniline, followed by
oxidation. One of the four patients evaluable for response
entered complete remission. No new or unexpected safety
findings were observed; the most common adverse events
were nausea and stomatitis.
Conclusions The PK profile of barasertib is similar to
previous studies using the same dosing regimen in patients
with AML. The majority of barasertib-hQPA clearance
occurred via hepatic metabolic routes.
Keywords Barasertib  Acute myeloid leukemia 
Pharmacokinetics  Metabolism  Phase I
Introduction
Acute myeloid leukemia (AML) is the most common type
of acute leukemia in adults, with a median age of onset of
72 years [1]. The Surveillance Epidemiology and End
Results registries analysis found that 86 % of patients aged
over 60 years died within 1 year of AML diagnosis [2],
attributed in part to their lack of tolerability of intensive
chemotherapy regimens, a higher incidence of poor risk
cytogenetic abnormalities and a higher incidence of multi-
drug resistant gene expression leading to ineffectiveness of
chemotherapy [3, 4].
Aurora kinases are a family of serine/threonine protein
kinases (Auroras A, B and C) known to play an important
role in the regulation of mitosis and chromosomal segre-
gation [5]. Aurora B kinase is involved in the spindle
assembly checkpoint component of the mitotic process and
is overexpressed in a variety of cancers [6]; several studies
have highlighted a role for Aurora B kinase in oncogenic
transformation [7, 8]. Increased expression of both Aurora
A and Aurora B kinases has been demonstrated in AML
Results have previously been presented at the American Society
of Hematology (ASH) Annual Meeting, San Diego, 9–13 December
2011 (Blood 2011;118:abstract 2,602).
M. Dennis (&)  M. Davies
The Christie NHS Foundation Trust, Wilmslow Road,
Manchester M20 4BX, UK
e-mail: mike.dennis@christie.nhs.uk
S. Oliver  R. D’Souza  L. Pike  P. Stockman
AstraZeneca, Alderley Park, Macclesfield, UK
123
Cancer Chemother Pharmacol (2012) 70:461–469
DOI 10.1007/s00280-012-1939-2
cell lines and in primary samples taken from patients with
AML [9, 10].
Barasertib is a pro-drug that is rapidly converted into its
more active moiety, barasertib-hydroxyquinazoline-pyr-
azol-aniline (barasertib-hQPA), following parenteral
administration in vivo [11]. Barasertib-hQPA is a revers-
ible, selective ATP-competitive inhibitor of Aurora B
kinase [11, 12]. Barasertib has demonstrated tumor growth
inhibition in solid human cancer tumor xenograft models,
such as lung and colorectal cancers [13]. Further, barasertib
has been shown to inhibit growth and survival of human
AML cells [10, 14]. Clinical studies have indicated that
barasertib treatment has an acceptable tolerability profile in
patients with newly diagnosed, relapsed, and advanced
AML [15, 16]. These studies also included exploratory
assessment of the pharmacokinetic (PK) profile of bara-
sertib. In this study, the PK, metabolic and excretion pro-
files of barasertib and barasertib-hQPA were assessed in




Eligible patients were aged C18 years with relapsed or
refractory AML for which no standard therapies were
anticipated to be effective, or with newly diagnosed AML
not considered to be suitable for standard induction and
consolidation chemotherapy for medical, social or psy-
chological reasons. All patients were required to have a
World Health Organization (WHO) performance status of
0–2; serum creatinine B1.5 9 upper limit of normal (ULN)
or 24-hour creatinine clearance [50 mL/min; serum bili-
rubin B1.5 9 ULN (unless considered due to leukemic
organ involvement; Gilbert’s or related syndrome
allowed); aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) B2.5 9 ULN (also unless con-
sidered due to leukemic organ involvement). Exclusion
criteria included hemoglobin levels B10.0 g/dL; QTc
interval C470 ms; central nervous system disease; partic-
ipation in a clinical study in which an investigational
product was received within 14 days of the first dose in this
study; or if they had received any chemotherapy or radio-
therapy within 14 days of start of study treatment.
Study design
This was an open-label, single-arm, single-center, Phase I
study. Patients received barasertib 1,200 mg as a 7-day
continuous intravenous infusion every 28 days. On Day 2
of Cycle 1 only, patients also received [14C]-barasertib
(250 lCi), administered as a 2-hour infusion. Based on
preclinical studies in rat and dog, it was expected that an
adequate recovery of total radioactivity, and thus compre-
hensive metabolite profiling, would be achieved following
the administration of the specified [14C]-barasertib regimen
(data on file). On the completion of the [14C]-barasertib
infusion, administration of non-radiolabeled barasertib
resumed for the remainder of the 7-day infusion period.
Following Cycle 1, each patient could receive subsequent
treatment cycles until disease progression or any other
discontinuation criteria were met. For Cycle 1, patients
remained as in-patients for up to 9 days following the start
of the 7-day barasertib infusion (7 days of dosing plus 2
additional days for observation). For all subsequent cycles,
patients were hospitalized for the infusion period only.
The 1,200 mg barasertib dose was the maximum toler-
ated dose (MTD) previously identified in the Phase I/II
dose-escalation study conducted in AML patients [15] and
was the therapeutic dose for subsequent Phase II investi-
gation in AML. The amount of radioactivity (250 lCi;
9.25 MBq) administered was considered to be the mini-
mum required to achieve the study objectives. All patients
provided written informed consent. The trial was approved
by all relevant institutional ethical committees or review
bodies and was conducted in accordance with the Decla-
ration of Helsinki, the International Conference on
Harmonization/Good Clinical Practice and the AstraZene-
ca policy on Bioethics [17].
Study objectives
The primary objective was to assess the PK, metabolism
and excretion profiles of barasertib and barasertib-hQPA
following a single 7-day intravenous infusion, including a
short infusion of [14C]-barasertib, to patients with AML.
Secondary objectives were to assess the safety and tolera-
bility of barasertib and to evaluate preliminary efficacy by
measurement of individual patient response (based on the
International Working Group AML clinical response cri-
teria [18]).
Assessments
Samples of blood, urine and feces were collected prior to
study treatment and at various time points during Cycle 1.
Blood samples were collected approximately 30 min prior
to start of infusion (SOI) on Day 1 (barasertib) and Day 2
([14C]-barasertib), and then every 24 h until Day 10
(216 h) and on Days 14 and 18 (312 and 408 h, respec-
tively). In addition, samples were collected on Day 2: 1 h
following the start of the [14C]-barasertib infusion ([14C]-
SOI), 5 min prior to the end of [14C]-barasertib infusion
([14C]-EOI), and at 15 min, 1, 2, 4 and 8 h following [14C]-
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EOI; and on Day 8: 5 min prior to the end of the barasertib
infusion (EOI), and at 15 min, 1, 2, 4, 6 and 10 h following
EOI. A urine sample was collected within the 24-hour
period prior to barasertib-SOI; feces samples within this
24-hour period were also collected. A urine sample was
collected within the 24-hour period following barasertib-
SOI. Further, urine and feces samples were collected
within 24-hour periods following [14C]-SOI: 0–24, 24–48,
48–72, 72–96, 96–120, 120–144, 144–168 and 168–192 h.
Barasertib and barasertib-hQPA concentrations in
plasma and urine were measured using liquid chromatog-
raphy tandem mass spectrometry following solid-phase
extraction (plasma) or dilution (urine). Plasma measure-
ments were determined by an independent bioanalytical
facility (PRA International—Early Development Services,
Assen, The Netherlands). The lower limit of quantification
(LLOQ) was 0.25 ng/mL for plasma samples and 1.00 lg/mL
for urine samples. Radioactivity in weighed aliquots of
plasma, urine, feces, whole blood and dose material was
determined by liquid scintillation counting (LSC). Radio-
activity concentrations in plasma and whole blood, and
percentage dose excreted in urine and feces samples were
calculated using LabLogic Debra 5TM (version 5.4.10.51).
For metabolite profiling, plasma samples that were col-
lected 5 min prior to [14C]-EOI for each patient were
prepared using 5 % formic acid in acetonitrile; extraction
efficiencies were all[91 %. Extracts were concentrated to
dryness and reconstituted in water/acetonitrile (95:5 v/v).
Pooled urine samples were freeze-dried and then recon-
stituted in methanol (duplicate extracts); extraction effi-
ciencies were all[94 %. The two extracts were combined,
concentrated to dryness and reconstituted in water/aceto-
nitrile (95:5 v/v). Pooled feces samples were extracted with
hexane followed by 3 9 5 % formic acid in acetonitrile;
extraction efficiencies ranged from 86 to 98 %. The first
two 5 % formic acid/acetonitrile extracts were combined,
concentrated to a small volume and reconstituted in water/
acetonitrile (95:5 v/v). Metabolite profiling was determined
using high-performance liquid chromatography–radiometric
(HPLC-RAD) methodology, with metabolites identified by
HPLC coupled with mass spectrometry (HPLC-MSn).
Efficacy was assessed according to the International
Working Group for AML trials criteria [18]. Adverse
events (AEs) were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events (CTCAE), version 3.0 [19].
Statistical analysis
No formal statistical analyses were planned; all objectives
were assessed descriptively. Previous experience with mass
balance studies found that a sample size of six patients was
sufficient to adequately characterize the rates and routes of
excretion of [14C]-labeled compounds [20, 21]. All patients
who received at least one dose of barasertib and for whom
post-dose data were available were included in the
assessment of safety and efficacy. Patients were included in




Between November 2009 and June 2010, six patients were
enrolled in this study. One patient died before receiving
any study treatment; the remaining five completed Cycle 1
and were therefore included in the PK and safety analysis
sets. Three of these five patients completed at least one
further treatment cycle. One patient started Cycle 2 on Day
36 after a 7-day delay due to logistical reasons; this patient
also started Cycle 3 on Day 78 but discontinued treatment
on the same day due to worsening of the disease. The
second patient also started Cycle 2 on Day 36 after a 7-day
delay in order to allow for hematological recovery and
subsequently received Cycle 3, starting on Day 64. The
third patient started Cycle 2 on Day 57 for logistical rea-
sons. The baseline demographic and disease characteristics
were representative of the intended patient population for
this study (Table 1). At the time of data cutoff (August 20,
2010), and for those patients who had received barasertib,
one patient was still on treatment, two patients had pro-
gressed, one patient had withdrawn due to lack of response,
and one patient had died due to an AE.
Pharmacokinetic parameters
Maximal plasma concentrations of barasertib and barasertib-
hQPA were achieved by the first scheduled sample, taken
24 h from the SOI (Fig. 1a). During the infusion period,
the geometric mean plasma concentration of barasertib-
hQPA was approximately threefold higher than that of
barasertib (Table 2); this is consistent with previous studies
[15, 16]. Following the EOI, plasma concentrations of
barasertib fell rapidly, reaching the LLOQ by 6 h after
EOI; it was therefore not possible to determine the terminal
elimination half-life (t), total clearance (CL) or volume of
distribution (V) of barasertib. In contrast, barasertib-hQPA
plasma levels declined in a triphasic manner, with a rapid
initial phase (with plasma concentrations decreased to one-
third of the plasma steady-state concentration within 2 h
post-EOI) followed by a slower decline thereafter. Low
concentrations (*4 ng/mL) of barasertib-hQPA were still
detectable at the final sampling point of 408 h (Day 18;
Fig. 1a); the terminal elimination phase had a mean t of
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66.3 h (Table 2). Barasertib-hQPA was extensively dis-
tributed to the tissues, with a relatively slow rate of total
clearance (Table 2). For four patients, maximum plasma
radioactivity concentration was achieved 5 min prior to
[14C]-EOI; for the remaining patient, this was achieved 1 h
prior to [14C]-EOI. The concentrations of radioactivity in
whole blood were lower than in plasma (with a ratio
approximating 0.7) at all time points examined (Fig. 1a).
Urine concentrations of barasertib were below LLOQ at all
time points; during the infusion period, the geometric mean
urine concentrations of barasertib-hQPA were approxi-
mately 4–5 lg/mL, declining rapidly following EOI. The
renal clearance values for barasertib-hQPA represent
approximately 10 % of the total clearance of barasertib-
hQPA from plasma (Table 2).
Recovery of total radioactivity
The target dose of [14C]-barasertib was 250 lCi; the actual
dose received ranged from 231 to 268 lCi. Overall,
72–82 % of total radioactivity was recovered, with
approximately double the amount recovered in feces
(mean ± SD, 51 ± 6.6 %) compared with urine
(mean ± SD, 27 ± 5.5 %; Fig. 1B). There was large inter-
patient variability in the rate of recovery of radioactivity in
feces: the majority ([40 %) of radioactivity was recovered
by 120 h in three patients, while in the remaining two
patients, the majority ([44 %) was recovered during the
last two time points (144–192 h) and it was evident that
radioactivity was still being eliminated in feces after the
end of the sample collection period. In contrast, the
excretion of radioactivity in urine occurred predominantly
within 72 h and was almost complete by 96 h from the
[14C]-SOI.
Metabolite profiling
Representative chromatographs for HPLC-RAD analyses
of plasma, urine and feces samples are presented in Fig. 2.
In plasma, the main metabolite was barasertib-hQPA; a
large proportion of unmetabolized barasertib was also
detected in plasma samples. Overall, the main excreta
metabolites identified were the following: barasertib-hQPA
(range, 13.2–33.7 %); barasertib-hQPA N-acetic acid
Table 1 Patient demographics and baseline characteristics
Barasertib 1,200 mg
n = 6
Median age (range), years 63 (34–74)
Male/female, n 3/3
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Fig. 1 Barasertib and barasertib-hQPA recoverability a Geometric
mean plasma concentrations of barasertib and barasertib-hQPA, and
total radioactivity [14C] in plasma and whole blood, versus time.
Arrowhead indicates start of barasertib infusion; arrow indicates end
of barasertib infusion. b Cumulative mean (± standard deviation)
percentage radioactivity dose recovered in urine, feces and combined.
The assessment time points are from the start of 14C-SOI
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(range, 7.8–10.5 %); barasertib-hQPA desfluoroaniline
N-acetic acid (range, 5.1–9.5 %); N-formyl or ethoxy
barasertib-hQPA (range, 3.5–9.2 %); and barasertib-hQPA
desfluoroaniline (range, 1.6–4.5 %). Unlike plasma, des-
fluoroaniline metabolites made up a significantly larger
proportion of the metabolites in excreta (*15 % compared
with *2 % in plasma) (Table 3). No glutathione or
epoxide metabolites were detected in any samples. The
main pathways identified in human metabolism of bara-
sertib were (1) cleavage of the phosphate group to form
barasertib-hQPA, followed by oxidation; and (2) loss of the
fluoroaniline moiety to form barasertib-hQPA desfluoro-
aniline, followed by oxidation.
Safety
There were no dose interruptions or dose reductions during
the study. The most common AEs (any grade; any cause)
were nausea and stomatitis (n = 4 each); stomatitis and
febrile neutropenia were the only grade C3 AEs reported in
more than one patient (Table 4). Grade C3 AEs were
experienced by three patients. One patient experienced
febrile neutropenia and stomatitis (both grade 3); a second
patient reported febrile neutropenia, stomatitis, anemia,
abdominal distension, gingival bleeding, neutropenic sep-
sis, hypocalcemia, hypomagnesemia and lethargy (all
grade 3). The third patient experienced febrile neutropenia
and thrombocytopenia (both grade 4); this patient subse-
quently experienced grade 5 multi-organ failure, which was
the only death during the study and was considered unre-
lated to study treatment (this patient had marrow failure
with neutropenia as a consequence of AML; this became
complicated by septicemia). Abnormalities in some
hematological, clinical chemistry and urinalysis results
were observed, which were consistent with the patients’
underlying disease. There were no clinically relevant
changes in vital signs or ECG measurements.
Efficacy
Four patients were evaluable for disease response. One
patient achieved a complete response (commenced Cycle 3,
Day 92; duration *6 months; a 73-year-old female with a
complex abnormal karyotype who had previously failed
hypomethylating therapy); the cytogenetic profile of this
patient at screening was ‘‘adverse complex.’’ No response
was observed in the remaining three patients.
Discussion
This small Phase I study defined the PK, metabolic and
excretion profiles of barasertib and barasertib-hQPA in
patients with newly diagnosed, relapsed or refractory
AML. We do not consider that the interpretation of our
results is substantially affected by the smaller than pre-
specified study population (n = 5). The PK profiles of
barasertib and barasertib-hQPA determined here are in
Table 2 Pharmacokinetics of barasertib and barasertib-hQPA in plasma and urine
Sample (n) Parametera Barasertib Barasertib-hQPA
Plasma (4)b AUC, ng.h/mLc NC 40,400 (0.4)
AUC(0–t), ng.h/mL
c 13,840 (0.4) 40,080 (0.4)
AUC(0–192 h), ng.h/mL
c NC 38,230 (0.4)
CSS, ng/mL
c 85.6 (0.5) 226.8 (0.4)
CL, L/h NC 31.4 (11.3)
t, h NC 66.3 (36.1)
kZ, h–1 NC 0.02 (0.02)
VSS, L NC 669.1 (344.9)
VZ, L NC 2805 (1708)
Urine (5) Ae, mg NC 96.9 (47.2)
CLR, L/h NC 2.85 (1.6)
fe % NC 8.1 (3.9)
AUC, area under plasma concentration–time curve; CSS, steady-state drug concentration; CL, total clearance; t, terminal half-life; kZ, slowest
disposition rate constant; VSS, volume of distribution (apparent) at steady state; VZ, volume of distribution (apparent) during terminal (kZ) phase;
Ae, cumulative amount of unchanged drug excreted; CLR, renal clearance of drug from plasma; fe, fraction of drug excreted into urine; NC, not
calculable
a All values are arithmetic mean (standard deviation) except where indicated. b Due to sampling issues, plasma concentration data were excluded
for one patient. c Values indicate geometric mean (coefficient of variation)
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agreement with those previously reported for patients with
advanced AML [15, 16], and similar findings have also
been reported in patients with solid tumors following bar-
asertib administration by various infusion schedules [22].
Barasertib is rapidly absorbed, and conversion to bara-
sertib-hQPA leads to an approximate threefold higher
mean plasma concentration of barasertib-hQPA compared
with barasertib. As observed previously, the fourfold
difference between the volumes of distribution (apparent)
during steady state versus the terminal phase indicates
that the majority of barasertib-hQPA is eliminated before
the distribution equilibrium in the tissue is achieved.
Thus, the time to a steady-state concentration of bara-
sertib-hQPA is governed by distribution kinetics rather
than its much longer t (arithmetic mean, 66.3 h). Fur-
ther, the ratio of radioactivity in plasma to whole blood
(approximately 0.7) indicated that barasertib is associated
with a greater degree with the plasma fraction compared
with the cellular components of the blood. Data from a
previous in vitro study showed that between 89.8 and
97.2 % of barasertib was bound to human plasma proteins
(data on file).
From the PK analysis, the renal clearance values for
barasertib-hQPA (4–15 % of the total clearance of
barasertib-hQPA from plasma) suggested that the majority
of clearance of barasertib-hQPA occurred via non-renal,
hepatic metabolic routes. From our radiolabeled studies,
we identified that the major route of elimination was via
feces, although the recovery rate showed high inter-patient
variability.
This study is the first to characterize the metabolic
pathway of barasertib in humans. Metabolites were
observed in this study that had not been previously iden-
tified in rat or dog plasma and excreta (data on file), sug-
gesting that these species may not provide good models for
the metabolic fate of barasertib in man. Barasertib is
metabolized by a number of pathways in humans. The
predominant pathway is the conversion to barasertib-
hQPA, which is subsequently followed by oxidation.
Another major metabolic pathway leads to the loss of the
fluoroaniline moiety to form a desfluoroaniline metabolite,
also followed by oxidation. Cleavage of the nitrogen bond
between the quinazoline and pyrazole ring systems fol-
lowed by oxidation and/or conjugation was found to be a
minor pathway. Another minor pathway was cleavage of
the ethyl group on the alkyl side chain of barasertib-hQPA.
Fluoroaniline metabolites detected were mainly conjugates
(both glucuronides and sulfates), and no glutathione or
epoxide metabolites were detected in any samples. In
plasma, the major components were barasertib and barasertib-
hQPA, indicating that the majority of metabolism occurs once
the drug has been distributed to the tissues.
In our study, no new or unexpected safety findings were
reported with barasertib. The most common AEs were
nausea and stomatitis; stomatitis and febrile neutropenia














































































































































































































































Fig. 2 Representative HPLC-RAD chromatographs for analyses of
plasma, urine and feces samples. a Plasma sample collected 5 min
prior to the end of the [14C]-barasertib infusion; b Urine sample
collected 0–24 h from start of the [14C]-barasertib infusion; c Pooled
feces sample collected 144–192 h from start of the [14C]-barasertib
infusion. CPM counts per minute
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patient. The AEs encountered were as expected for this
patient population and are consistent with those reported in
previous studies of barasertib in AML [15, 16].
One complete remission was reported in this small
patient population, suggesting that barasertib mono-
therapy may have potential as a treatment strategy in this
challenging setting. Indeed, in Phase I studies in both
Japanese and Western patients with AML, treatment
with barasertib was associated with response rates of
19–25 % [15, 16]. The preliminary efficacy observed in
this patient population warrants further investigation.
Studies are also assessing the combination of barasertib
and low-dose cytosine arabinoside in patients aged
C60 years with AML; in one Phase I, safety and toler-
ability study, the combination was found to have an
acceptable tolerability profile with a preliminary signal
for efficacy [23].
In conclusion, barasertib and barasertib-hQPA exhib-
ited similar PK profiles to those previously observed in
patients with solid tumors and AML. We have charac-
terized the metabolic profile of barasertib and have shown
that barasertib metabolites are eliminated predominantly
via the feces. The safety profile of barasertib was as
expected, and the drug was tolerated in this population.
Table 3 [14C]-barasertib and metabolite peaks identified in plasma and excreta extracts; components [1 % of chromatogram radioactivity or
dose are listed






Plasmab,c Barasertib-hQPA 34.33–35.20 508 48.27–56.61
Barasertib 37.97–38.57 588 17.26–26.53
Barasertib-hQPA N-acetic acid 40.43–40.77 522 1.42–5.29
N-formyl or ethoxy barasertib-hQPA 37.00–37.87 536 4.24–4.42
Barasertib-hQPA desfluoroaniline N-acetic acid 14.33–14.71 429 1.33–2.21d
Barasertib-hQPA desfluoroaniline 11.30–11.70 415 2.05e
Excreta Barasertib-hQPA 31.00–35.50 508 13.15–33.70
Barasertib-hQPA N-acetic acid 39.10–41.47 522 7.83–10.52
Barasertib-hQPA desfluoroaniline N-acetic acid 13.70–18.07 429 5.07–9.45
N-formyl or ethoxy barasertib-hQPA 46.13–47.10 536 3.47–9.24
Barasertib-hQPA desfluoroaniline 11.57–18.07 415 1.60–5.48
Ketone of barasertib-hQPA desfluoroaniline 10.67–13.13 429 1.73, 4.88e
Ketone of barasertib-hQPA desfluoroaniline 4.30–4.90 429 0.88–4.19
N-formyl or ethoxy barasertib-hQPA 36.00–39.07 536 0.96–3.86
Barasertib-hQPA N-oxide 37.63–38.60 524 0.21–2.96
Ketone of barasertib-hQPA desfluoroaniline 13.70–14.20 429 0.34, 2.37f




Ketone of barasertib-hQPA or N-desethyl
N-acetyl metabolite
43.00–44.70 522 5.65g
a Data presented for plasma are expressed as % of chromatogram radioactivity; data presented for excreta are presented as % of administered
dose
b Measurements from one patient are omitted due to sampling error
c Two unidentifiable metabolites were detected in two patients
d Confirmed by mass spectrometry only in one patient
e Confirmed by mass spectrometry only in three patients
f Detectable in two patients only
g Detectable in one patient only
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Preliminary efficacy findings indicate potential for benefit
in this patient population, which warrants further
investigation.
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